Patents by Inventor Gert KISS

Gert KISS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240116878
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: March 21, 2023
    Publication date: April 11, 2024
    Inventors: Elena S. KOLTUN, Kevin MELLEM, Adrian GILL, Gert KISS, Christopher SEMKO, Naing AAY, Andreas BUCKL, Ashutosh JOGALEKAR, Walter WON
  • PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20240092795
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: April 25, 2023
    Publication date: March 21, 2024
    Inventors: Adrian GILL, Naing AAY, Kevin MELLEM, Andreas BUCKL, Elena S. KOLTUN, Christopher SEMKO, Gert KISS
  • Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
    Patent number: 11739093
    Abstract: The present disclosure is directed to compounds of Formula IV: as inhibitors of SHP2 and their use in the treatment of diseases associated with SHP2. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 29, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Brian R. Blank, Jennifer Pitzen, Gang Wang, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Elena S. Koltun, Naing Aay, Andreas Buckl, Kevin Mellem, Christopher Semko, Ash Jogalekar, Gert Kiss, Adrian Gill
  • C26-linked rapamycin analogs as mTOR inhibitors
    Patent number: 11685749
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: June 27, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Christopher Michael Semko, Gang Wang, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Micah James Evans Gliedt, Jennifer Pitzen, Julie Chu-Li Lee, Walter Won, Arun P. Thottumkara, Adrian Liam Gill
  • Pyridine compounds as allosteric SHP2 inhibitors
    Patent number: 11673896
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: June 13, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Adrian Gill, Naing Aay, Kevin Mellem, Andreas Buckl, Elena S. Koltun, Christopher Semko, Gert Kiss
  • 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
    Patent number: 11661401
    Abstract: The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: May 30, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Kevin Mellem, Adrian Gill, Gert Kiss, Christopher Semko, Naing Aay, Andreas Buckl, Ashutosh Jogalekar, Walter Won
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20230100838
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Jennifer PITZEN, James AGGEN, G. Leslie BURNETT, Adrian L. GILL, Christopher SEMKO, Anne V. EDWARDS, Micah James GLIEDT, Gert KISS, Ashutosh JOGALEKAR, John E. KNOX, Andreas BUCKL, Elena S. KOLTUN
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20230093861
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: March 30, 2023
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20230055672
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20220340596
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2020
    Publication date: October 27, 2022
    Inventors: Christopher Michael SEMKO, Gang WANG, G. Leslie BURNETT, James Bradley AGGEN, Gert KISS, James Joseph CREGG, Micah James Evans GLIEDT, Jennifer PITZEN, Julie Chu-Li LEE, Walter WON, Arun P. THOTTUMKARA, Adrian Liam GILL
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20210338824
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 28, 2020
    Publication date: November 4, 2021
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
    Patent number: 10980889
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: April 20, 2021
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20210101870
    Abstract: The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: June 18, 2020
    Publication date: April 8, 2021
    Inventors: Elena S. KOLTUN, Kevin MELLEM, Adrian GILL, Gert KISS, Christopher SEMKO, Naing AAY, Andreas BUCKL, Ashutosh JOGALEKAR, Walter WON
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20210094975
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 1, 2021
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
  • 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
    Patent number: 10590090
    Abstract: The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 17, 2020
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Kevin Mellem, Adrian Gill, Gert Kiss, Christopher Semko, Naing Aay, Andreas Buckl, Ashutosh Jogalekar, Walter Won
  • BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20200017511
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 16, 2020
    Inventors: Brian R. BLANK, Jennifer PITZEN, Gang WANG, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Elena S. KOLTUN, Naing AAY, Andreas BUCKL, Kevin MELLEM, Christopher SEMKO, Ash JOGALEKAR, Gert KISS, Adrian GILL
  • PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20200017517
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 16, 2020
    Inventors: Adrian GILL, Naing AAY, Kevin MELLEM, Andreas BUCKL, Elena S. KOLTUN, Christopher SEMKO, Gert KISS
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20190336609
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2019
    Publication date: November 7, 2019
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS
    Publication number: 20190210977
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 11, 2019
    Inventors: Ashutosh JOGALEKAR, Walter WON, Elena S. KOLTUN, Adrian GILL, Kevin MELLEM, Naing AAY, Andreas BUCKL, Christopher SEMKO, Gert KISS